Non-Invasive Liquid Biopsy Screening
Our blood-based liquid biopsy screening analyzes thousands of small non-coding RNA from a single, routine blood draw. Harnessing diagnostic power from countless biologically significant sources across the enitre body.
​
Early Detection for
Hundreds of Cancers &
Disease States
Cancer Detection
MicroRNAs in the blood have emerged as powerful biomarkers, creating a novel pathway for the early detection and diagnosis of cancer, potentially even before the disease fully develops. These have the ability to reflect changes in cellular processes long before clinical symptoms or traditional imaging methods can detect abnormalities.
By analyzing circulating miRNAs through liquid biopsy, clinicians can identify dysregulated molecular signatures associated with cancer initiation, offering a minimally invasive method to monitor individuals at high risk and intervene at the earliest possible stage. This capability positions miRNA analysis as a crucial component in the evolution of precision medicine, enabling proactive management and significantly improving patient outcomes.
Disease Detection
MicroRNAs in the blood are increasingly recognized as versatile biomarkers with the potential to revolutionize diagnostics across a wide range of disease states, including neurological, pulmonary, muscular, and hematological disorders.
These small, non-coding RNA molecules play critical roles in regulating gene expression and can reflect underlying pathophysiological changes in various tissues and organs.
The stability of miRNAs in the bloodstream and their tissue-specific expression patterns make them ideal candidates for non-invasive diagnostics, enabling early detection and monitoring of these diverse disease states. By harnessing the diagnostic potential of circulating miRNAs, healthcare providers can move toward earlier interventions, personalized treatment strategies, and improved outcomes across a broad spectrum of diseases.
Drug Validation
Biomarkers play a crucial role in the validation of drugs and biologics with the FDA, serving as measurable indicators of biological processes, disease states, or responses to treatment. They help demonstrate the efficacy, safety, and mechanism of action of new therapies, guiding regulatory approval and clinical use. MicroRNAs, with their ability to reflect changes in gene expression and disease progression, hold significant potential as biomarkers for validating drug outcomes.
By monitoring specific miRNA profiles in response to treatment, researchers can gain insights into how a drug is affecting the disease at a molecular level, providing early evidence of efficacy or identifying potential adverse effects. This capability could streamline the drug development process, offering a novel and precise method for validating therapeutic outcomes and ensuring that new treatments are both effective and safe for patients.
Validated TBI Diagnositc
Our Traumatic Brain Injury Diagnostic is validated with diagnostic for
Based on microRNA (miRNA) analysis, this offers a precise and non-invasive method to detect brain injury by identifying specific miRNA signatures in the blood, enabling early and accurate assessment of TBI.